Literature DB >> 19776774

Trombotic microangiopathy: can liver-kidney transplantation cure aHUS?

Hae Il Cheong.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19776774     DOI： 10.1038/nrneph.2009.148

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 2.  Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

3.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

4.  Eculizumab for congenital atypical hemolytic-uremic syndrome.

Authors:  Ralph A Gruppo; Russell P Rother
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

5.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Chantal Loirat; Sylvie Cloarec; Marie-Alice Macher; Jacques Blouin; Hubert Nivet; Laurence Weiss; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2004-12-08       Impact factor: 10.121

6.  Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.

Authors:  J M Saland; S H Emre; B L Shneider; C Benchimol; S Ames; J S Bromberg; G Remuzzi; L Strain; T H J Goodship
Journal:  Am J Transplant       Date:  2006-08       Impact factor: 8.086

Review 7.  Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.

Authors:  Elena Bresin; Erica Daina; Marina Noris; Federica Castelletti; Rumen Stefanov; Prudence Hill; Timothy H J Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2005-11-02       Impact factor: 8.237

8.  Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Authors:  Christoph J Mache; Birgit Acham-Roschitz; Veronique Frémeaux-Bacchi; Michael Kirschfink; Peter F Zipfel; Siegfried Roedl; Udo Vester; Ekkehard Ring
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-25       Impact factor: 8.237

9.  Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Benjamin L Shneider; Jonathan S Bromberg; Patricia A Shi; Stephen C Ward; Margret S Magid; Corinne Benchimol; Mouin G Seikaly; Sukru H Emre; Elena Bresin; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 8.237

Review 10.  Complement and the atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Marina Noris; Véronique Fremeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714
  10 in total
  1 in total

Review 1.  New immunosuppressive agents in pediatric transplantation.

Authors:  Christina Nguyen; Ron Shapiro
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.